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Abstract
3,4-Methylenedioxymethamphetamine (MDMA or ecstasy) is a popular recreational drug that has
been shown to induce loss of brain serotonin (5-HT) neurons. The purpose of this study was to
determine the usefulness of pharmacological magnetic resonance imaging (phMRI) in assessing
5-HT dysfunction by examining the hemodynamic response evoked by infusion with the selective
5-HT reuptake inhibitor citalopram. We studied the effects of MDMA on brain hemodynamics
using arterial spin labeling (ASL) based phMRI following a citalopram challenge (7.5 mg/kg, i.v.),
combined with [123I]β-CIT SPECT imaging in ten male MDMA users and seven healthy non-users.
Single photon emission computed tomography (SPECT) imaging was used to assess the availability
of 5-HT transporters (SERT). Imaging results were comparedwith the results of behavioralmeasures
and mood changes following drug administration, in both groups (using the Beck Depression Inven-
tory, Barratt Impulsiveness Scale and a visual analog scale). Reductions in SERT binding were
observed in the occipital cortex of MDMA users. In line with this, citalopram induced decreases in
cerebral blood flow (CBF) in the occipital cortex of MDMA users. ASL based phMRI also detected a
CBF decrease in the thalamus of MDMA users. In concordance with imaging findings, behavioral
measures differed significantly between MDMA users and controls. MDMA users had higher impulsiv-
ity scores and felt more uncomfortable after citalopram infusion, compared with control subjects.
Our findings indicate that phMRI is very well suited for in-vivo assessment of 5-HT dysfunction.
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Elsevier B.V. and ECNP. All ri1. IntroductionghtDisturbances of the serotonergic (5-HT-ergic) system have been
linked to several neuropsychiatric disorders. The serotonin
transporter (SERT) is located on the presynaptic membrane of
5-HT neurons and plays a crucial role in the reuptake of 5-HT
and in modulating 5-HT concentrations in the synaptic cleft.s reserved.
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photon emission computed tomography (SPECT) and positron
emission tomography (PET), using ligands for SERT or 5-HT re-
ceptors. Several groups observed reduced SERT binding in recre-
ational 3,4-methylenedioxymethamphetamine (MDMA) users,
by using SPECT or PET imaging (de Win et al., 2008a; McCann
et al., 2005; Reneman et al., 2001). SPECT and PET imaging
however, depend on the use of radioactive tracers, rendering
them less suitable for pediatric studies or for repeated
measurements.
A promising technique to investigate the 5-HT system is
pharmacological magnetic resonance imaging (phMRI). In
phMRI, a neurotransmitter specific pharmacological challenge
is given, causing changes in neurovascular coupling and subse-
quent region specific hemodynamic changes. The selective se-
rotonin reuptake inhibitor (SSRI) citalopram increases 5-HT
release by inhibiting the reuptake of 5-HT. It has been used pre-
viously in phMRI studies and has been proven an adequate probe
of 5-HT function (Attenburrow et al., 2001; Seifritz et al., 1996;
Anderson et al., 2007; McKie et al., 2005; Rose et al., 2006;
Wingen et al., 2008). Whereas in previous studies, the blood ox-
ygenation level dependent (BOLD) signal was used to visualize
hemodynamic changes, nowadays perfusion MRI by arterial
spin labeling (ASL) is also more frequently used (Chen et al.,
2011; Hagino et al., 1998; Ogawa et al., 1990; Rao et al.,
2000; Khalili-Mahani et al., 2011). ASL is a non-invasive perfu-
sion imaging modality that uses magnetically labeled blood
water protons as an endogenous tracer of cerebral blood flow
(CBF). By subtracting labeled and unlabeled images, a CBF
map is generated, which can be used for visualization and quan-
tification of CBF (Golay et al., 2004) with sufficient precision
(Gevers et al., 2011). It has been shown that ASL based phMRI
gives a more precise measurement of pharmacologically in-
duced hemodynamic changes (Tjandra et al., 2005).
MDMA itself has already been used in phMRI to assess its ef-
fects on the 5-HT system (Brevard et al., 2006). Brevard et al.
(2006) suggested in their discussion that MDMA-induced 5-HT
neurotoxicity would probably be an adequate model to test
the applicability of phMRI in assessing 5-HT dysfunction.
McKie et al. (2005) already investigated 5-HT function in
healthy humans using BOLD based phMRI. The usefulness of
phMRI in assessing 5-HT dysfunction in humans, however, has
not yet been studied.
The purpose of this study was to determine whether ASL
based phMRI is a useful method in assessing 5-HT dysfunction by
examining hemodynamic responses evoked by citalopram infu-
sion in MDMA users and healthy controls. The results of ASL
based phMRI with an intravenous citalopram challenge were
combined with SPECT imaging and behavioral measures. Thus,
comparisons could bemade between imaging findings,measures
of SERT binding and the behavioral consequences of MDMA-
induced changes to the serotonergic system. We hypothesized
that inMDMAuserswewould observea reduction in hemodynam-
ic response evoked by citalopram, in brain regions with reduced
SERT densities, as citalopram binds highly selective to the SERT.
2. Experimental procedures
2.1. Subject recruitment and study design
Subjects were recruited by advertisements and word of mouth. After
written informed consent, 10 male MDMA users and 7 healthy malecontrols were included in the study. The eligibility criterion for the
MDMA group was previous use of more than 50 tablets of MDMA. The
cutoff point of 50 tablets was based on previous studies (Reneman et
al., 2001). The 7 control subjects were healthy subjects with no self-
reported prior use of MDMA. Participants agreed to abstain from use
of MDMA and other psychoactive drugs for at least 2 weeks before
the studies and were asked to undergo urine drug screening on the
days of assessment (with an enzyme-multiplied immunoassay for am-
phetamines, including MDMA). Exclusion criteria were: a positive
drug screen, any neuropsychiatric diagnosis or history of brain disease
or injury, use of medication with affinity for SERT (e.g., SSRIs), or any
contra-indication to MRI such as metallic implants or claustrophobia.
The local institutional Medical Ethics Committee approved the study.
2.2. Behavioral measures
We selected two widely used tests for assessment of mood and impul-
sivity, as 5-HT plays a central role in mood regulation and impulsivity:
the Beck Depression Inventory (BDI, Beck, 1961) was administered as a
self-report estimate of mood and the Barratt Impulsiveness Scale (BIS
version 11, Patton et al., 1995) as a self-report estimate of impulsivity.
In addition, drug effects and mood changes following citalopram
infusion were assessed using simulated visual analog rating scales
(VAS) 5 min before and 5 min after scanning, rating on a scale of 1 to
10 for anxious feelings, tension, feeling comfortable or uncomfort-
able, light-headedness, wakefulness, drowsiness and nausea.
2.3. Procedures
Subjects underwent phMRI followed by SERT SPECT after a two to
four week interval (range 17–31 days, mean 21.7±5.2 days). For
the phMRI scan, 7.5 mg citalopramhydrochloride obtained from
Lundbeck GmbH (Hamburg, Germany), was diluted in 45 mL of sa-
line solution. The drug was infused after 7.5 min of baseline scan-
ning over a period of 7.5 min in order to examine the effects of
citalopram on the hemodynamic response. This timeframe was
based upon previous studies investigating the hemodynamic effects
of citalopram infusion (McKie et al., 2005). Post-infusion imaging
was performed during 22.5 min, resulting in a total scanning dura-
tion of 37.5 min.
2.4. MR imaging
All MR imaging was performed using a 3.0 T Philips MR scanner
equipped with a SENSE 8-channel head coil and body coil transmission
(Philips Medical Systems, Best, The Netherlands). Each session proto-
col consisted of a high resolution 3DT1-weighted anatomical scan for
registration and segmentation purposes and a phMRI sequence. For
the phMRI sequence, a pulsed ASL sequence was used, that was
based on the PULSAR sequence developed by Golay (Golay et al.,
2005). phMRI imaging parameters were: TR/TE 3000/14 ms; FOV
240×240 mm2; matrix size 80×79; 17 slices; thickness 7 mm; no gap;
gradient echo single shot EPI; SENSE 2.0; post-labeling delay 1.2 to
2 s; number of dynamics 375. One dynamic consisted of a control and
a labeled image. The labeling plane was positioned parallel to the
imaging volumewith a labeling gap between the center of the imaging
volume and the labeling volume of 90 mm. We acquired 75 dynamics
at baseline, 75 dynamics during infusion and 225 dynamics post-
infusion.
2.5. MR processing
FSL 4.1 (FMRIB-Software-Library, Functional Magnetic Resonance
Imaging of the Brain Center, Dept. of Clinical Neurology, University
of Oxford, Oxford, UK, http://www.fmrib.ox.ac.uk), the SPM toolbox,
Freesurfer image analysis suite, (http://surfer.nmr.mgh.harvard.
5395-HT phMRIedu/) and Matlab (The MathWorks Inc., Natick, USA) were used for off-
line data processing.
Subtraction of labeled and control ASL images yielded whole
brain perfusion weighted images. The mean equilibrium magnetiza-
tion (M0) of arterial blood per subject was calculated, from which
the absolute CBF was computed following the methods outlined by
Chalela et al. (2000). The resulting ASL images were averaged over
25 volumes (2.5 min) to increase the signal-to-noise ratio (SNR).
This resulted in 15 separate time bins.
3DT1 anatomical scans were segmented into gray and white mat-
ter. Perfusion weighted images were transformed into anatomical
space by an affine registration of the mean volumes per time bin
to the gray matter masks of corresponding anatomical scans. An iso-
tropic resampling of 3.0 mm was chosen.
The structural images were non-rigidly normalized to a
population-based average using Diffeomorphic Anatomical Registra-
tion Through Exponentiated Lie Algebra (DARTEL) (Ashburner,
2007), to allow for a voxel-based analysis. The non-rigid transforma-
tions were applied to the ASL volumes that were previously regis-
tered to gray matter masks, such that all dynamics of all subjects
resided in one common frame of reference. Finally, a Gaussian
smoothing with FWHM=6 mm was applied to all volumes (Fig. 1).
2.6. SPECT imaging
The subjects were examined using SPECT with the SERT ligand 123I-
labeled 2β-carbomethoxy-3β-(4-iodophenyl)tropane ([123I]β-CIT).
SPECT images were obtained in 10 MDMA users and 7 healthy controls,
however one SPECT scan had to be excluded due to poor image quali-
ty. 123I-labeledβ-CIT was prepared as previously described (Reneman
et al., 2001). Potassium iodide was used to block thyroid uptake of
free radioactive iodide. SPECT images were acquiredwith a brain ded-
icated SPECT system (Neurofocus, an update of the Strichman Medical
Equipment 810X, Strichman Medical Equipment Inc., Medfield, Mass.,
USA). This is a 12-detector single-slice scanner with a full width at half
maximum resolution of 6–7 mm. The acquisition of SPECT images was
the same as previously described (de Win et al., 2005) and was
commenced 4 h after i.v. injection of approximately 112 MBq
(3.02 mCi) [123I]β-CIT since at this time peak specific binding to
SERTs has been reached (Pirker et al., 2000).
2.7. SPECT processing
Reconstruction and attenuation correction of all images were
performed as previously described (Booij et al., 1997). To be able to
correct the image for background radioactivity (non-specific binding)
a predefined ROI was placed over the cerebellum. The ROI was placed
on the three consecutive SPECT slices with the highest counts. For
analysis, the Statistical ParametricMapping software (SPM 8WellcomeFigure 1 (a) An axial slice of the perfusion measured with ASL,
averaged over time in 375 dynamics. (b) Averaged ASL-image over
subjects after non-rigid normalization (see text). Notice the pres-
ervation of anatomical detail, suggesting good alignment between
subjects.Department of Imaging Neuroscience, Functional Imaging Laboratory,
London, UK; http://www.fil.ion.ucl.ac.uk/spm) was used. All scans
were realigned to an arbitrarily chosen subject, after which an aver-
age template was calculated. Subsequently, the scans were
co-registered and normalized to this template. The registered scans
were intensity-scaled to the corresponding mean cerebellar non-
specific counts per voxel, obtained from the ROI analysis (de Win
et al., 2008b).3. Statistical analysis
All data were analyzed in SPSS version 17.0 (SPSS Inc, Chicago,
IL) and are presented as mean±SD unless otherwise indicated.3.1. Characteristics of the sample and behavioral
measures
Differences in continuous variables were analyzed using un-
paired 2-tailed student's t-tests unless stated otherwise and
ordinal data were compared using chi-square tests.3.2. SPECT and phMRI studies
Analysis of SPECT and phMRI datasets was carried out using a
voxel-based analysis.
Unpaired t-testing was used to compare differences
between groups to evaluate the overall group effects ASL
and SPECT datasets. The chance of a type I error was set at
0.01 to correct for multiple comparisons.
Paired t-testing was used to compare differences within
groups, to analyze the effects of the citalopram challenge in
the ASL datasets. Weights were chosen to represent a post-
infusion increase [−1, 0, 1] or decrease [1, 0, −1]. By applying
this statistical model to ASL phMRI data, the response to the
challenge was determined for both healthy controls and
MDMA users. In addition, the interaction between group and
challenge effects was also calculated, to determine to what
extent groups reacted differently to the challenge.
The SPECT datasets were analyzed as previously de-
scribed (de Win et al., 2008a). A minimal cluster size of
ten voxels was maintained, besides the significance thresh-
old of 0.01, to correct for multiple comparisons.4. Results
Group characteristics are presented in Table 1. Controls and users
of MDMA differed slightly but statistically significantly in age
(p=0.02). Mean cumulative dose of MDMA was 281 tablets and
time since last dose 2.1 months. Although the MDMA users had
used on average more recreational drugs such as alcohol, amphet-
amine and cocaine, this difference was not statistically
significant.4.1. Behavioral measures
BIS scores were significantly higher for users of MDMA than control
subjects (74.0±8.7 vs. 54.3±9.1, p=0.02), but we did not observe
a group difference in BDI scores (5.1±5.6 vs. 2.7±2.5; n.s.).
Table 1 Characteristics of drug abuse and alcohol exposure.
MDMA Controls p-
valuen=10 n=7 a
Age 25.4 (±2.1) 21.3 (±3.9) 0.02
Last 3 months use of
Alcohol, no. times used NS b
None 1 0
10–19 0 2
20–39 4 3
>40 5 1
Tobacco, no. cigarettes NS b
None 5 6
1–5 cig./day 2 0
6–20 cig./day 2 0
>20 cig./day 1 0
Cannabis, no. times used NS b
None 4 5
1–5 3 0
10–39 2 1
>40 1 0
Amphetamine, gr 0.3±0.7 0±0 0.16 c
Cocaine, no. lines 0.8±1.6 0±0 0.21 c
Characteristics of ecstasy use
Duration of use (years) 6.5±3.1
Lifetime exposure (tot. no. tablets) 281±250.97 [range 50–900]
Usual dose (no. tablets/occasion) 3.65±3.08
Time since last tablet (months) 2.14±2.34
a Drug history questionnaire missing for 1 control subject.
b Chi-square test.
c Log transformed.
540 M.L.J. Schouw et al.Overall, citalopram infusion was well tolerated, apart from
one of the MDMA users experiencing an acute increase in light-
headedness and nausea short after infusion.
VAS scores showed statistically significant decreases in tension
in the control subjects (pb0.01) as well as feeling less sweaty andTable 2 Behavioral measures.
Controls
Mean (SD)
BDI 2.7 (±2.5)
BIS 54.3 (±9.1)
VAS Controls MDMA
Δpost−pre (SD) p-value Δpost
Alert −1.1 (1.9) n.s. −0.8
Tense −2.3 (1.4) 0.005 −0.5
Calm 0.3 (1.4) n.s. −0.9
Clammy −0.7 (0.8) 0.05 −0.5
Comfortable 0.4 (1.0) n.s. −1.4
Nausea 0 (0) n.a. 0 (0.9
Sleepiness 1.1 (1.6) n.s. 1.0 (1
Light-headedness 0.7 (1.6) n.s. 1.6 (2
Sweaty −2.1 (1.6) 0.02 −1.2
Uncomfortable −0.3 (0.8) n.s. 0.5 (2clammy (p=0.02 and p=0.05) when comparing pre- to post-
infusion (Table 2). MDMA users were more lightheaded before
infusion (p=0.03) when compared to control subjects, but other
parameters did not statistically differ from controls before citalo-
pram infusion. After infusion, MDMA users felt significantly moreMDMA users p-value
Mean (SD)
5.1 (±5.6) n.s.
74.0 (±8.7) b0.01
users Controls vs. MDMA users
−pre (SD) p-value p-value pre p-value post
(2.3) n.s. n.s. n.s.
(1.9) n.s. n.s. n.s.
(1.6) n.s. n.s. n.s.
(2.0) n.s. n.s. n.s.
(2.9) n.s. n.s. 0.02
) n.s. n.s. n.s.
.8) n.s. n.s. n.s.
.8) n.s. 0.03 0.02
(2.6) n.s. n.s. n.s.
.7) n.s. n.s. 0.05
Figure 2 Statistical parametric map of [123I]ß-CIT SPECT bind-
ing ratios. The yellow cluster represents statistically significant
lower binding SPECT ratios in the left anterior occipital lobe of
MDMAusers when compared to controls in the axial (a) and sagittal
(b) plane. The image is superimposed on a T1 anatomical atlas
from SPM. Scale bar indicates z-scores. Statistic images were
thresholded with a cluster significance threshold of p=0.01.
5415-HT phMRIlightheaded (p=0.02), uncomfortable (p=0.02) and tense
(p=0.04) than controls.
4.2. SPECT imaging
SERT binding ratios were significantly reduced in the left anteri-
or part of the occipital lobe of MDMA users when compared to
controls (Fig. 2).
4.3. ASL based phMRI
4.3.1. Challenge effect
Administration of citalopram to control subjects did not result
in marked CBF changes compared to baseline (with a p=0.01Figure 3 Statistical parametric map of CBF change induced by 7.
users show both a decrease (a) and increase (b) in CBF in response
right frontal and right occipital cortex (panel A). The significant clu
is located close to the central sulcus and probably reflects remaining
effect. An increase in CBF was also observed in the thalamus, in addit
bar indicates z-scores. Statistic images were thresholded a cluster sthreshold). MDMA users showed a statistically significant CBF
decrease in response to the 5-HT challenge that was most promi-
nent in the left thalamus (Fig. 3 panel A). In addition, a CBF de-
crease was observed in the right occipital cortex and in the right
frontal cortex. Also, a significant CBF increase was noted in the
left globus pallidus and left frontal cortex (Fig. 3 panel B).
4.3.2. Group effect
Baseline mean whole brain CBF in MDMA users was significantly
higher in MDMA users than in controls (mean users 49.4±9.1 mL/
100 g/min vs. mean controls 44.1±9.4 mL/100 g/min, pb0.01,
see Fig. 4). However, there was no whole brain response to the
citalopram challenge on the CBF measurements.
When comparing the changes in CBF before and after the
challenge (ΔCBF) between groups, the ΔCBF in MDMA users in re-
sponse to the 5-HT challenge differed statistically significantly
from the ΔCBF in controls. This ΔCBF (a decrease) was present
particularly in the left thalamus and several regions in the bilat-
eral anterior occipital lobe of MDMA users (Fig. 5). No CBF in-
creases in response to the challenge were observed when
comparing the two groups.5. Discussion
The most important findings of our study are threefold.
Firstly, we observed a statistically significant CBF decrease
in the occipital cortex of male MDMA users in response to a
5-HT challenge with the SSRI citalopram. SPECT imaging
revealed statistically significant lower SERT binding ratios
in the occipital cortex of male MDMA users when compared
to control subjects. Secondly, ASL based phMRI showed5 mg citalopram in MDMA users. Effect of the challenge: MDMA
to the challenge. A decrease in CBF was noted in the thalamus,
ster of decreased CBF in the prefrontal cortex/cingulate gyrus
intravascular label and is not to be considered a true challenge
ion to the left globus pallidus and frontal cortex (Panel B). Scale
ignificance threshold of p=0.01.
Figure 6 Statistical parametric map of [123I]ß-CIT SPECT bind-
ing ratios. The yellow cluster represents statistically significant
lower binding SPECT ratios in the right parieto-occipital and
anterior-occipital lobes of MDMA users when compared to controls
in the sagittal (a) and axial (b) plane. The image is superimposed
on the mean SPECT scan from all subjects. Scale bar indicates z-
scores. Statistic images were thresholded with a cluster signifi-
cance threshold of p=0.001.
Figure 4 Whole brain CBF data in MDMA users and healthy con-
trols indicating statistically significant higher mean CBF values in
users vs. controls during the entire scanning period.
542 M.L.J. Schouw et al.significantly higher mean whole brain CBF in MDMA users
than in controls. Also, ASL based phMRI showed a significant
group effect in the left thalamus that was not observed in
the SPECT study. Thirdly, MDMA users had higher impulsivity
scores on a standardized impulsivity scale which correlated
with SERT densities and hemodynamic changes in the occip-
ital cortex. Furthermore, they felt significantly more un-
comfortable after the citalopram infusion compared to the
control subjects. The combination of imaging findings and
behavioral measures suggests that MDMA-induced changes
to the serotonergic system can be visualized using phMRI.
Only one other study has exclusively studied male MDMA
users with [123I]β-CIT SPECT (Semple et al., 1999). Similar
to that study, we observed lower SERT binding in the occipital
lobe of male MDMA users when compared to controls (Semple
et al., 1999). The occipital cortex seems particularly sensitive
to effects of MDMA because it shows the largest reductions in
SERT densities in human and experimental studies (Kish
et al., 2010; McCann et al., 2008; Szabo et al., 2002). In mod-
erate users, reductions have only been observed in parieto-
occipital and occipital cortex (Reneman et al., 2001).
To support the SPECT findings of this study performed in a
relatively small population, we reanalyzed [123I]β-CIT SPECT
of 21 male MDMA users (mean age 26.6 years) and 6 male
controls (29.2 years), who participated in a previous study ofFigure 5 Statistical parametric map of CBF changes induced by
7.5 mg citalopram in MDMA users compared to control subjects.
Group effect: Statistically significant lower CBF in the left
thalamus, and bilateral occipital lobe in response to a citalopram
injection in MDMA users when compared to healthy controls
superimposed on the time- and subject-averaged CBF. Scale bar
indicates z-scores. Statistic images were thresholded a cluster
significance threshold of p=0.01.our group (Reneman et al., 2001) using the same methods as
described in the current study. MDMA users had used on aver-
age 487 tablets (+/−679), whereas controls had never been ex-
posed to MDMA. In this larger sample of male MDMA users with
a (much) higher MDMA exposure, voxel-based analysis con-
firmed our present findings of reduced SERT binding ratios in
the anterior occipital cortex (see Fig. 6), in addition to the
parieto-occipital cortex. Our current SPECT findings involving
‘only’ a specific brain region of MDMA users are thus in concor-
dance with literature and previous data of male MDMA users.
Other studies involving both male and female MDMA users ob-
served reductions in SERT also in other brain regions (e.g.,
Reneman, 2001; McCann et al., 1998; de Win et al., 2008a).
Therefore, it has been suggested that women are more sensi-
tive than men to MDMA-induced reductions in SERT binding
(Buchert et al., 2004; Reneman et al., 2001).
We used the SSRI citalopram as a pharmacological chal-
lenge. One could argue on the choice for this SSRI, since it
might also induce a general vascular response. However,
McBean et al. (1999) demonstrated in rats that local CBF
changes in response to a citalopram challenge are correlated
to changes in glucosemetabolism rather than reflecting a gen-
eral vascular response. Furthermore, in higher doses citalo-
pram does not alter cardiovascular parameters (Penttila
et al., 2001; Seifritz et al., 1996). In the current study, citalo-
pram evoked hemodynamic changes in a number of specific
brain regions in MDMA users, but not in control subjects. The
pattern of hemodynamic changes appeared to be related to
the release of 5-HT, as the strongest hemodynamic changes
were observed in cortical regions and subcortical gray matter
(areas such as putamen and thalamus, with a high SERT density
in healthy subjects), and not as much a general vascular
response.
As hypothesized, we observed a reduced hemodynamic
response in the occipital cortex of MDMA users with SERT
5435-HT phMRIreductions.We hypothesized that a reduction in hemodynamic
response in brain regions with reduced SERT densities would
reflect reduced 5-HT transmission and thus reduced 5-HT me-
diated changes in neuronal activity. There is indeed accumu-
lating evidence that reductions in hemodynamic responses
reflect decreases in neuronal activity. Preece et al. (2009)
have shown region specific increases in BOLD signal evoked
by the 5-HT releaser fenfluramine. Interestingly, pre-
treatment with the inhibitor of 5-HT synthesis p-
chlorophenylalanine attenuated this BOLD response, suggest-
ing that the BOLD signal is sensitive to increased availability
of 5-HT. Jenkins et al. (2004) performed an experiment similar
to ours, investigating the dopaminergic system in 1-methyl-4-
phenyl 1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys
using phMRI. They observed a reduction in regional cerebral
blood volume evoked by the dopamine releaser amphetamine.
This response correlated well with decreases in dopamine
transporter availability. The fact that ASL based phMRI
detected CBF changes in a brain region that was also identified
by significant differences in SPECT binding and previously
mentioned in literature, suggests that phMRI is a powerful
tool for assessment of 5-HT dysfunction (Kish et al., 2010;
McCann et al., 2008; Reneman, 2001; Semple et al., 1999;
Szabo et al., 2002).
Interestingly, we observed a 12% higher overall CBF in
MDMA users. This observation is in line with previous studies,
in which 5-HT has been described to modulate cerebral perfu-
sion. It has been suggested that after the initial excessive
release of 5-HT induced by MDMA, normalization or even
depletion of 5-HT at a later time point results in an increase
in CBF, due to MDMA-induced loss of 5-HT neurons (Chang
et al., 2000; Reneman et al., 2000).
ASL based phMRI showed an additional brain region (the thal-
amus) in which a group difference was detected, unlike SPECT.
Besides the occipital cortex, the thalamus is a brain region that
is particularly sensitive to MDMA's effects (de Win et al., 2008b;
McCann et al., 2005, 2008). Therefore, ASL based phMRI seems
very well suited for assessing 5-HT dysfunction. It has been
reported that ASL is not hampered by signal drifts, as it mea-
sures one single physiological parameter (CBF) and has a greater
inter-subject reliability compared to BOLD (Tjandra et al.,
2005). If ASL phMRI is a better technique than BOLD phMRI in
evaluating 5-HT dysfunction, remains to be assessed.
BIS impulsivity scores were higher in users of MDMA than in
control subjects. This observation was described previously by
our study group in a prospective study cohort (de Win et al.,
2006). This indicates that the increase of impulsivity scores is
at least partly due to MDMA use rather than a pre-existent
personality trait in users, even after exposure to only a few
tablets of MDMA. Interestingly, MDMA users also felt more
uncomfortable after citalopram infusion when comparing to
control subjects who felt more comfortable, providing further
evidence that MDMA users and control subjects in this study
not only differ in 5-HT mediated changes in neuronal activity,
but also in behavior. The significant difference in impulsivity
scores and the perception of drug effects and mood changes
following citalopram infusion are in line with the challenge ef-
fects that were observed phMRI and reduced SERT density in
users observed by SPECT.
Several limitations of this study should be recognized. First
of all, the sample size of the control group is relatively small.
The results from the SPECT data however, are in accordancewith previous findings. For this reason, the phMRI results
should be replicated in larger groups to confirm our findings.
Secondly, the groups we studied differed slightly but signifi-
cantly in age. In literature, different values for the variability
of 5-HT receptor and transporter availability with age have
been reported. Generally, it seems that the availability of 5-
HT transporters differs greatly between subjects. This differ-
ence exceeds the difference that would be introduced by the
mean age difference present in our study population
(Buchert et al., 2006; Parsey et al., 2002; Ryding et al.,
2004). In line with this, we did not observe a significant effect
of age on SERT binding (p=0.87), and the results of our study
were not affected by introducing age as a covariate: the effect
of group remained significant (p=0.03). Thirdly, in this cross
sectional study design, we had to rely upon the self-reported
use of drugs of abuse and alcohol. Theoretically, the present
findings could be due to other drugs than MDMA, since MDMA
users had more experience with other recreational drugs.
However, there was no significant difference in the use of
other recreational drugs between groups. Fourthly, one
might ascribe reductions in occipital SERT to direct pharmaco-
logical effects. This is unlikely however, since participants had
to abstain from psychoactive drugs for at least two weeks be-
fore data acquisition. The latter was screened for by urine
drug screening at the day of examination. Thirdly, it is possi-
ble, that pre-existing differences between MDMA users and
controls underlie differences in SERT densities and brain activ-
ity evoked by citalopram. However, previous longitudinal neu-
roimaging studies only observed changes in the thalamus of
incidental MDMA users (de Win et al., 2008b). Finally, the
fact that ASL phMRI did not reveal any citalopram response
in our controls could be attributable to the spatial resolution
with which ASL data were acquired. We did however observe
clear responses to citalopram in MDMA users, indicating that
responses in this group were large enough to overcome possi-
ble resolution issues. Moreover, imaging alterations in users
were in concordance with behavioral measures in this group.
Therefore, we believe that the results of the current study
clearly show the effects of MDMA on the brain and that these
effects can be imaged by ASL based phMRI.
In conclusion, this study provides evidence that citalopram
phMRI is a powerful new and non-invasive tool for assessment
of 5-HT dysfunction.We observed a reduction in hemodynamic
response in a brain region with reduced SERT densities, pre-
sumably reflecting 5-HT mediated changes in neuronal activi-
ty. MDMA users and control subjects differed in 5-HTmediated
changes in neuronal activity, a finding that was confirmed by
the difference in behavioral measures between both groups.
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